KANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing ...
SPRING HOUSE, Pa., June 2, 2021 /PRNewswire/ -- Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA ® (guselkumab), ...
Responder analyses demonstrate statistically significant symptom resolution across multiple endpoints in PL9643-treated patients compared to placebo. 6 of 13 symptom endpoints reached statistical ...
Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...
Impact of steroids indication on the efficacy of immunotherapy in a multi-tumor cohort of patients: Time and dose-dependent evaluation.
Once-daily formulation of dexmethylphenidate achieved primary endpoint (p 0.001) with consistent symptom relief up to 12 hours post-dose KANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback